More on MLYS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-44.2% Growth)
- Ratings (8.3 Score)

Upcoming Events

- Earnings (11/16/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Mineralys Therapeutics (NQ:MLYS)
Delayed: 20.30 -1.34 (6.19%)
Prev. Close $21.64  
Open$21.60 
52 Wk High$ 
52 Wk Low$ 
Day High$21.60 
Day Low$20.12 
P/E N/A  
EPS$ 
Volume1,181,247 

Friends, Peers and Foes (?): AMGN, IRON, JNJ, LLY, LXRX (more...)

Oct 13, 2026 04:11 PM Form 144 Mineralys Therapeutics, Filed by: Rodman David Malcom
Oct 12, 2026 06:52 AM H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Oct 12, 2026 02:24 AM UBS Starts Mineralys Therapeutics, Inc. (MLYS) at Neutral
Oct 9, 2026 09:00 AM Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Oct 2, 2026 05:53 PM Form 4 Mineralys Therapeutics, For: Sep 30 Filed by: Congleton Jon
Oct 2, 2026 04:30 PM Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
Oct 1, 2026 04:05 PM Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Sep 30, 2026 04:08 PM Form 144 Mineralys Therapeutics, Filed by: Congleton Jon
Sep 29, 2026 04:05 PM Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Sep 28, 2026 11:50 AM Form 4 Mineralys Therapeutics, For: Sep 22 Filed by: Slingsby Brian Taylor
View All Articles

Entities mentioned with MLYS

View All Entities